Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 11
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 09-142
Study First Received: December 2, 2009
Last Updated: April 21, 2015
Estimated Primary Completion Date: July 2012
Primary Outcome Measures:
To Determine the Rate of Clinical Benefit (i.e. Rate of Complete or Partial Response Plus Stable Disease) at 16 Weeks for Patients With Malignant Mesothelioma Treated With Everolimus as Second or Third Line Therapy.
Sponsors and Collaborators:
Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals|Dana-Farber Cancer Institute|University of Pennsylvania
Website Link: https://ClinicalTrials.gov/show/NCT01024946
